Our client’s research addresses difficult treatment decisions in children with autoimmune and autoinflammatory diseases. After earning his medical degree at Istanbul University, he completed pediatric residency training, a master’s degree in pediatric autoinflammatory diseases, and a pediatric rheumatology fellowship at Hacettepe University. He subsequently became an assistant professor at Lokman Hekim University while practicing pediatric rheumatology at Koru Ankara Private Hospital, combining specialist care with research and medical education.
Our firm presented an EB-1A petition emphasizing his original research and the recognition it had received within the profession. Key contributions included a score designed to predict colchicine resistance in familial Mediterranean fever and research on structured reduction and withdrawal of canakinumab treatment. His scholarly publications, conference recognition, and peer-review service for journals such as the European Journal of Pediatrics supported the presentation of his professional standing. We connected these achievements to specific clinical challenges, including identifying patients who may need alternative treatment and assessing when therapy can be reduced.
The evidence captured a distinctive aspect of his work: studying both the need for stronger disease control and opportunities to limit treatment exposure. That focus gave the petition a clear account of how his research could inform individualized care for children facing chronic inflammatory conditions. USCIS approved his I-140 petition under the EB-1A Extraordinary Ability category, supporting his plans to continue advancing pediatric rheumatology through clinical research and diagnostic innovation in the United States.
